CD163 and neoplasm: We aim to determine changes and distribution of CD163+ immune cell levels in specific tumor regions (tumor nest and tumor stroma) of PT, LNM and DM, and evaluate potential associations of CD163 levels at these distinct sites with clinicopathological characteristics and survival (PFS and OS).